NASDAQ:INGN Inogen (INGN) Stock Price, News & Analysis $7.51 -0.16 (-2.09%) As of 09:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Inogen Stock (NASDAQ:INGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Inogen alerts:Sign Up Key Stats Today's Range$7.41▼$7.8050-Day Range$5.87▼$7.7052-Week Range$5.70▼$13.33Volume182,241 shsAverage Volume285,288 shsMarket Capitalization$203.07 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingModerate Buy Company Overview Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California. Read More Inogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreINGN MarketRank™: Inogen scored higher than 88% of companies evaluated by MarketBeat, and ranked 275th out of 1,876 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingInogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageInogen has only been the subject of 2 research reports in the past 90 days.Read more about Inogen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inogen are expected to grow in the coming year, from ($1.73) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inogen is -7.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inogen is -7.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInogen has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Inogen's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.35% of the float of Inogen has been sold short.Short Interest Ratio / Days to CoverInogen has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inogen has recently decreased by 9.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInogen does not currently pay a dividend.Dividend GrowthInogen does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-1.12 Percentage of Shares Shorted3.35% of the float of Inogen has been sold short.Short Interest Ratio / Days to CoverInogen has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inogen has recently decreased by 9.56%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.92 News SentimentInogen has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Inogen this week, compared to 3 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.46% of the stock of Inogen is held by insiders.Percentage Held by Institutions89.94% of the stock of Inogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inogen's insider trading history. Receive INGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter. Email Address INGN Stock News HeadlinesNeedham Sticks to Its Buy Rating for Inogen (INGN)August 17 at 6:12 AM | theglobeandmail.comInogen Inc’s Earnings Call Highlights Growth and InnovationAugust 13, 2025 | msn.comWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.August 18 at 2:00 AM | Porter & Company (Ad)Inogen Second Quarter 2025 Earnings: Beats ExpectationsAugust 10, 2025 | finance.yahoo.comInogen Announces Second Quarter 2025 Financial ResultsAugust 9, 2025 | finance.yahoo.comInogen, Inc. (INGN) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comInogen Inc (INGN) Q2 2025 Earnings Call Highlights: Steady Growth Amidst ChallengesAugust 8, 2025 | gurufocus.comInogen: Earnings Uncertainty Weakens Valuation Argument (Rating Downgrade)July 21, 2025 | seekingalpha.comSee More Headlines INGN Stock Analysis - Frequently Asked Questions How have INGN shares performed this year? Inogen's stock was trading at $9.17 on January 1st, 2025. Since then, INGN shares have decreased by 18.6% and is now trading at $7.46. How were Inogen's earnings last quarter? Inogen, Inc (NASDAQ:INGN) posted its earnings results on Thursday, August, 7th. The medical technology company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.07. The medical technology company had revenue of $92.28 million for the quarter, compared to analysts' expectations of $90.40 million. Inogen had a negative net margin of 7.58% and a negative trailing twelve-month return on equity of 13.77%. Read the conference call transcript. Who are Inogen's major shareholders? Inogen's top institutional investors include Kent Lake PR LLC (3.92%), Acadian Asset Management LLC (3.78%), Ameriprise Financial Inc. (3.26%) and Armistice Capital LLC (2.46%). View institutional ownership trends. How do I buy shares of Inogen? Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inogen investors own include American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/07/2025Today8/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:INGN CIK1294133 Webwww.inogen.com Phone(805) 562-0500FaxN/AEmployees1,030Year Founded2001Price Target and Rating Average Price Target for Inogen$11.00 High Price Target$14.00 Low Price Target$7.00 Potential Upside/Downside+47.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.89 million Net Margins-7.58% Pretax Margin-7.78% Return on Equity-13.77% Return on Assets-8.52% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio2.67 Sales & Book Value Annual Sales$335.70 million Price / Sales0.60 Cash FlowN/A Price / Cash FlowN/A Book Value$7.30 per share Price / Book1.02Miscellaneous Outstanding Shares27,040,000Free Float26,645,000Market Cap$201.72 million OptionableOptionable Beta1.72 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:INGN) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inogen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Inogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.